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Summary
Objective: To investigate the relationship between biochemical markers in the synovial fluid of osteoarthritic and contralateral equine joints
and gross articular cartilage pathology.
Design: Twenty-two horses underwent bilateral arthroscopy of their carpal or metacarpophalangeal joints following recent onset lameness.
The degree of cartilage damage in each joint was scored and synovial fluid, from both the clinically affected and the contralateral joint, was
collected. Bone specific alkaline phosphatase (BAP), 5D4 epitope of keratan sulphate (KS), total glycosaminoglycans (GAG) and hyaluronan
(HA) were measured.
Results: The mean age of the horses was 4.1 years and the maximum duration of lameness was three months. Joints examined were
midcarpal, antebrachiocarpal and metacarpophalangeal. The median concentration (semi-interquartile range) of BAP was significantly
higher in the clinically active joint than in the contralateral joint, 21.75 (6.22) vs. 12.35 (4.07) units, while the other biomarkers measured were
significantly lower in the clinically active joint than in the contralateral joint, i.e. KS 8.79 (1.96) g/ml vs. 16.39 (5.65) g/ml, KS:GAG ratio 0.19
(0.04) vs. 0.31 (0.10) and HA 741.6 (222) g/ml vs. 1061.75 (325) g/ml. BAP was positively (R=0.57), and KS (R= −0.57) and KS:GAG ratio
(R= −0.49) were negatively correlated to the degree of cartilage damage within the joint.
Conclusion: The correlation between articular cartilage damage and synovial fluid BAP and KS imparts validity to their potential use as
non-invasive diagnostic aids in equine osteoarthritis (OA). The positive correlation between BAP and cartilage damage suggests that there
is a link between bone turnover and cartilage damage in OA. © 2001 OsteoArthritis Research Society International
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In order to maximize the potential of any therapeutic
intervention in osteoarthritis (OA), it is essential to diagnose
the disease at an early stage. At present the diagnostic
techniques available are effective only once the disease is
well established, e.g. radiography, or involve invasive pro-
cedures, e.g. arthroscopy. The aim of molecular marker
research is to detect OA changes early and non-invasively,
before irreversible disease processes have occurred.
During normal metabolism joint tissue macromolecules
or fragments thereof are released into the synovial fluid,
and then into blood and urine. Biochemical or immuno-
chemical assays can be used to detect these molecules. In
OA changes in metabolism can produce compositional
changes in newly synthesized molecules and the result-
ing neoepitopes can be detected by immunochemical
methods. These macromolecules are thought to be bio-
markers of anabolic and catabolic processes in the major49tissues of the diarthrodial joints and may be used as tools
to detect levels of degradation or repair in the OA joint. A
number of biomarkers have been shown to be associated
with disease activity and outcome1–4 and investigation into
these markers is providing a wealth of information regard-
ing the metabolism of the joint tissues and the pathogenic
mechanisms involved in the development of OA.
The ideal marker of cartilage degradation is one which is
not found in normal cartilage or in any other tissue. It is also
one which can be validated against another form of
measurement, validity being defined as the extent to which
any instrument measures what it is supposed to measure.5
A valid measurement must correlate with a gold standard,
which in the case of joint disease is usually radiography or
magnetic resonance imaging (MRI). Since the degener-
ation of articular cartilage has long been accepted as the
pivotal diagnostic feature of OA, correlation between the
degree of cartilage damage and the change in concen-
tration of any biochemical marker from normal, in serum or
synovial fluid will give criterion validity to that marker.
Arthroscopy, although more invasive than radiography or
magnetic resonance imaging, allows direct visualization of
the cartilage, and recently has become the gold standard
for assessing cartilage lesions in vivo.6
For many years it has been accepted that cartilage has
been the most important tissue in the pathogenesis of OA
where the initiating events of proteoglycan loss followed byReceived 18 October 1999; accepted 29 April 2000.
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Synovial fluid samples were collected from 22 thorough-
bred racehorses in training, which underwent arthroscopic
examination of their joints after short periods of lameness.
Following clinical examination, intra-articular anesthesia
and radiography, OA, as defined by gross disruption to the
articular cartilage and, in some cases, to the subchondral
bone, was confirmed in one or both paired joints during
arthroscopy. The clinically affected joint was defined as that
principally responsible for the presenting lameness. In each
case the degree of cartilage damage in each joint was
scored, by the same observer (AB) in each case, according
to a scale adapted from that used by McIlwraith11 (Table I).
Synovial fluid, from both the clinically affected and the
contralateral joint, was collected into plain vacutainers
(Vacutainer Becton-Dickinson) at the time of surgery, while
the horses were under anesthesia. Samples were centri-
fuged at 4000 rpm for 10 min and the supernatants stored
in eppendorfs at −80°C until assays were carried out. Bone
specific alkaline phosphatase, KS, GAG, and HA were
measured in all synovial fluid samples.KERATAN SULFATE
An inhibition ELISA using the monoclonal antibody 5D4
was used to analyze samples for KS. Samples were
analyzed by ELISA inhibition using a method similar to that
described by Thonar et al. 1985 but with a few minor
modifications.12 Interassay and intra-assay coefficients ofvariation, calculated using both the 50% inhibition point of
each assay and the value of the control sample, were <5%.TOTAL GLYCOSAMINOGLYCANS
GAG levels were measured by dimethylmethylene blue
assay described by Farndale et al.13 and using a standard
bovine trachea chondroitin sulfate (Sigma) for calibration.
All samples were assayed in duplicate. The interassay and
intra-assay coefficient of variation were <7% and <12%
respectively.HYALURONAN ASSAY
This inhibition ELISA assay was adapted from a method
described by Goldberg.14 Ninety-six-well polystyrene
plates (outermost wells were excluded) were coated with
200 l of hyaluronan (Sigma) in a 20 mM sodium carbonate
buffer. The plates were incubated overnight at 4°C before
blocking with 1% bovine serum albumin (BSA)-PBS, and a
further 6 h incubation at 4°C. Before use plates were
washed twice with 0.05% Tween-PBS. HA was diluted in
0.05% Tween-PBS/1% BSA and double diluted to make a
standard curve ranging from 2000 ng/ml to 0.977 ng/ml.
Samples were diluted (serum 1:4 to 1:8) and 100 l added
in duplicate to the wells. PBS buffer was used as a blank,
and a control sample and an inhibition well were added to
check assay variation. One hundred microliters of 1 g/ml
human PG was added to all wells except the blanks. After
shaking for 20 s the plates were incubated overnight at
4°C. The plates were washed four times with Tween-PBS
before adding 200 l 5D4 antibody (ICN) to all wells and
incubating at 37°C for 1 h. After four further washes in
Tween-PBS 200 l of anti-mouse IgG alkaline phosphatase
conjugate (Sigma A-2179) in Tween-PBS/BSA was added
to each well. Plates were washed four times in Tween-PBS
and then 200 l of alkaline phosphatase substrate was
added to each well. After allowing 30 min at room tempera-
ture for development of color the color absorbance of the
plates were read on an automatic ELISA plate reader at
405 nm. The interassay and intra-assay coefficients of
variation for SF were 22% and 11%, respectively, and for
serum were 12% and 7.2%.BONE SPECIFIC ALKALINE PHOSPHATASE ASSAY
BAP levels were determined using a capture immuno-
assay available as a commercial kit (Alkphase-B; Metra
Biosystems). The assay uses a monoclonal purified murine
anti-BAP IgG antibody coated onto a microtitre stripwells to
capture BAP in the added sample. The enzyme activity of
the captured BAP is detected by a p-Nitrophenyl phosphate
(pNPP) substrate. BAP standards used are purified
from osteosarcoma SAOS-2 cells in a buffered solution.
Quantitation software (Deltasoft) with a quadratic curve
fitting equation was used on a Macintosh LC computer to
interpret values of unknowns from a linear standard curve.Table I
Scoring system used for the assessment of degree of cartilage
damage
Score Degree of articular cartilage damage
0 Normal.
1 Minimal articular cartilage damage.
2 Articular cartilage damage affecting up to 30% of the
articular surface of the bone.
3 Loss of up to 50% of the articular cartilage from the
affected carpal bone.
4 Severe loss of cartilage affecting more than 50% of the
articular surface.STATISTICS
Distribution of markers were found to be skewed,
therefore non-parametric methods were used. For com-
parison of markers in paired joints Wilcoxon signed rank
tests were used and correlations with arthroscopy scoreirreversible loss of collagen framework occur. However
more recently studies have shown that subchondral bone
changes may precede articular cartilage changes7 and if
this is so then it may be that bone may be the more
important tissue in OA research and development of thera-
pies. Bone specific alkaline phosphatase (BAP) is an
important marker of bone formation,8 playing an important
role in bone mineralization.9 No studies could be found in
the literature concerning the measurement of BAP in
equine synovial fluid, although in a canine study, BAP was
found to be increased in actively OA stifle joints when
compared to the contralateral joint.10
The aim of this study was to investigate the cross-
sectional differences between biochemical markers in
synovial fluid in equine OA and contralateral joints, and to
ascertain whether any relationship exists between the
markers and the level of articular cartilage damage in the
joint, in order to begin to validate the use of these markers
as diagnostic aids in equine OA.
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(Rs). Values were considered significant at or below 0.05,
and confidence intervals (CI) were stated at 95%.Results
Twenty-two horses underwent bilateral arthroscopic
examinations, and paired synovial fluid samples were avail-
able from all cases. The mean known age of the horses in
this group was 4.1 years and the duration of lameness
in any case did not exceed 3 months. Seventeen of the
22 horses were thoroughbreds in racing training. Of the
22 pairs of joints examined, 15 were midcarpal (MC),
four were antebrachiocarpal (ABC), and three were
metacarpophalangeal (MCP) (Table II).
The median concentration of the bone marker (BAP) was
significantly higher (P=0.002) in the clinically active joint
compared to the contralateral joint (Fig. 1).
In contrast, the HA concentration in clinically active joints
was significantly lower (P=0.01) than in the contralateral
joint (Fig. 2). Similar results were found with KS (P=0.001)
and the KS:GAG ratio (P=0.002) (Figs 3 & 5). There was
no significant difference between concentrations of GAG in
paired joints (Fig. 4).
There was no correlation between the clinically active
and the contralateral joint for concentration of any marker.
Bone specific alkaline phosphatase concentration in syno-
vial fluid was positively correlated, and KS and KS:GAG
ratios were negatively correlated to arthroscopy score of
cartilage damage. There was no significant correlation
between HA or GAG concentration and cartilage damage
within the joint. Correlations are shown in Fig. 6(a)–6(c).Table II
Arthroscopy cases with scores of cartilage damage
Case Age Breed Joint Clinically affected
joint score
Contralateral
joint score
1 ? ? MC 1 1
3 2 TB MC 2 1
4 9 Arab MCP 2 0
5 4 TB MCP 2 0
6 ? Hunter ABC 2 0
7 3 TB MC 2 1
8 7 TBX ABC 1 0
10 4 TB MC 2 1
14 2 TB MC 3 1
15 2 TB MC 2 1
16 4 TB MC 3 1
17 2 TB ABC 2 1
18 2 TB MC 2 1
19 2 TB MC 2 1
20 3 TB MC 3 1
21 ? TB MCP 1 0
22 5 TB MC 3 0
23 ? TB MC 0 0
24 3 TB MC 1 0
25 3 TB MC 3 0
28 13 Conn ABC 3 0
29 4 TB MC 3 0
Abbreviations: TB=thoroughbred, TBX=thoroughbred cross,
Conn=Connemara, MC=midcarpal, ABC=antebrachiocarpal,
MCP=metacarpophalangeal.
?=age not recorded.80
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Fig. 1. Comparison of BAP synovial fluid concentration between
paired clinically active OA and contralateral joints. The horizontal
bars indicate the median values.3000
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Fig. 2. Comparison of HA synovial fluid concentration between
paired clinically active OA and contralateral joints. The horizontal
bars indicate the median values.Discussion
The clearly significant differences in the concentration of
the biomarkers between active and contralateral joints
indicate that there are differences in the metabolism of the
joint tissues in clinically active and inactive contralateral
joints in OA. These markers may have clinical potential
in the cross-sectional assessment of OA in the horse,
particularly where paired samples are available.
52 C. J. Fuller et al.: Relationship between equine synovial fluid markers and articular cartilage damage80
0
ContralateralClinically active
70
50
40
20
10
60
K
S
 (
µg
/m
l)
30
Fig. 3. Comparison of KS synovial fluid concentration between
paired clinically active OA and contralateral joints. The horizontal
bars indicate the median values.180
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Fig. 4. Comparison of GAG synovial fluid concentration between
paired clinically active OA and contralateral joints. The horizontal
bars indicate the median values.1.4
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Fig. 5. Comparison of KS:GAG ratio in synovial fluid between
paired clinically active OA and contralateral joints. The horizontal
bars indicate the median values.The increased concentration of BAP in the synovial fluid
from active equine OA joints in this study supports the view
that bone is involved in the OA process from an early stage.
This finding has not been reported previously in the horse
although it has been demonstrated in the dog.10 The lower
concentrations of HA and KS in the synovial fluid of theclinically active joint are consistent with previous equine
studies.10,15,16 Moreover, the results also seem to be
consistent with several previous studies where markers of
joint tissue metabolism have been measured in paired
human joint fluids.17,18 In the former study,17 the 5D4
epitope, when expressed as a ratio of sulfated GAG, was
found to be lower in SF from the injured knee when
compared to the contralateral control knee. In the latter
study18 an increase in the concentrations of markers
(COMP fragments and stromelysin 1) was also found in the
uninjured contralateral knee, suggesting that the tissue
metabolism in the contralateral knee was also affected
following injury to the other knee. In our study, in the SF of
the contralateral joints the KS:GAG ratio was significantly
lower and the BAP concentrations were significantly higher
than in the SF in similar joints in a group of normal horses.
From this it could be interpreted that the contralateral joint
is not necessarily a true ‘normal’ for comparison. Indeed in
some of the contralateral joints there were signs of cartilage
damage which was scored at arthroscopy (Table II). Also, in
our study the horses from the normal group had a higher
mean age and were not racehorses in training, so although
the joints compared were similar we should be cautious in
making a direct comparison of marker values.
The positive correlation between synovial fluid BAP and
articular cartilage damage is a novel finding and demon-
strates a link between changes in bone and articular
cartilage in OA. Although focal cartilage loss is accepted to
be the primary characteristic of OA, subchondral bone has
been implicated in exacerbating the disease.19 Scinti-
graphical studies have also shown that increased bone
activity can precede joint failure20 and in a macaque model
of OA morphological bone alterations seemed to precede
cartilage changes.21 These findings emphasize the impor-
tance of bone involvement in the pathogenesis of OA,
which should be a major consideration when developing
new therapies.
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Fig. 6. Correlation between biomarker concentrations in synovial
fluid and arthroscopic score, indicating trendline. (a) BAP vs.
arthroscopy score R=0.57, 95%CI=0.31,0.75 P=0.0001; (b) KS
vs. arthroscopy score R= −0.57, 95%CI= −0.75,0.29, P=0.0002;
(c) KS:GAG ratio vs. arthroscopy score R= −0.49, 95%CI=
−0.7,0.19, P=0.002.
(a)
(b)
(c)There is, as yet, no established validated equine arthro-
scopy scoring system. The scoring system used in the
arthroscopic assessment in this study was adapted fromone previously used in equine arthroscopy studies.11,15 A
global score was used which allowed for both the size and
depth of the cartilage lesion, since this has previously
been reported to correlate well with the validated Societe´
Franc¸aise d’Arthroscopie grading system.22 In that study
the arthroscopy score correlated well with radiographic
variables and longitudinal change in score correlated sig-
nificantly with functional changes. The intraobserver vari-
ation using that method was found to be good.22 In 1996,
Ratcliffe et al.23 reported that in an arthroscopic study of the
glenohumeral joint in man, using a global grading scheme,
measurement of GAG, KS, and 3B3(−) correlated well with
the arthroscopic diagnosis of OA. Results from the veteri-
nary studies have been variable. In one study comparing
arthroscopy and radiology in assessment of carpal OA24
correlation between the two measurements was poor, while
in another study radiological changes in subchondral bone
were found to correlate well with arthroscopic findings.25
In our study the correlation between arthroscopic score
of cartilage damage and marker levels adds validity to the
use of synovial fluid BAP and KS in cross-sectional OA
assessment. Correlation between decreasing levels of KS
in the synovial fluid and moderate to severe OA assessed
arthroscopically is in opposition to the data presented by
Ratcliffe et al.23 but is in agreement with other KS data in
man.1,4 No significant correlation was found between syno-
vial fluid HA and articular cartilage damage, unlike in a
study by Tulamo,15 which reported a negative correlation.
This may be because the scoring system used did not
account for changes in the synovium which is the principle
source of HA.
Many studies have been carried out investigating cross-
sectional differences in synovial fluid markers. However,
caution must be employed when comparing results from
these different investigations. In the study reported here
the contralateral joints were used as controls. This does
not necessarily mean that the contralateral joints were
physiologically normal, but the control used was the same
type of joint from the same horse. This has the obvious
advantage of reducing error caused by individual variation.
In some studies OA joints are compared with normal joints,
but not necessarily the same type of joint, from other
horses. There is evidence for variability in synovial fluid
marker levels from different individuals26 and recently
differences in marker levels between different joints has
also been reported.27 Assays used to measure markers
also vary between studies. It is important that these vari-
ables are taken into account when making inferences and
comparisons in marker research.
Many different methods have been used to measure
BAP in horse sera, including the wheat germ precipitation
test28 and the immunoradiometric assay (Tandem-Ostase
Hybritech Belgium).29 As yet there are no published
data concerning the use of the assay employed in this
study (Alkphase-B Metra Biosystems) on equine samples.
Investigations into the use of this assay with human serum
samples have shown30 no cross reactivity occurring with
intestinal or placental alkaline phosphates, and only 3–8%
cross reactivity to the liver isoenzyme. The assay has been
used successfully in canine studies10 in both serum and
synovial fluid in which BAP activity was found to be
increased in clinically active OA joints.
Biochemical markers are being increasingly used as
measures of outcome in the assessment of disease modi-
fying osteoarthritis drugs (DMOADS).12,31 If these markers
are to be validated for this use more information is required
about the changes that occur in marker levels at different
54 C. J. Fuller et al.: Relationship between equine synovial fluid markers and articular cartilage damagestages of OA, and more baseline information must be
gained with respect to normal ranges and the effect of
variables such as joint site, age, and disease duration. This
study has shown that concentrations of BAP, KS, KS:GAG,
and HA are all significantly different in early OA compared
to contralateral joints and are therefore potentially useful as
cross-sectional markers in OA. Bone specific alkaline
phosphatase, KS and the KS:GAG ratio also show good
correlation with articular cartilage pathology, imparting
criterion validity to these markers which increases their
potential both as clinical tools and in the assessment of
disease modifying agents.Acknowledgments
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ABC Antebrachiocarpal joint
BAP Bone specific alkaline phosphatase
BSA Bovine serum albumin
CI Confidence interval
Conn Connemara
DMOADs Disease modifying osteoarthritis drugs
ELISA Enzyme linked immunosorbent assay
GAG Glycosaminoglycans
HA Hyaluronan
KS Keratan sulphate
kg Kilogram
MC Midcarpal joint
MCP Metacarpophalangeal joint
mg Milligram
ml Millilitre
MRI Magnetic resonance imaging
OA Osteoarthritis
PBS Phosphate bu#ered saline
PG Proteoglycan
PIP Proximal interphalangeal joint
SF Synovial fluid
SIQR Semi interquartile range
TB Thoroughbred
TBX Thoroughbred crossReferences
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